Chee Keong SeeDr. Malaysia

Dr See Chee Keong, graduated from University Putra Malaysia in 2006, completed MRCP (UK) in 2012 and Diabetes & Endocrinology fellowship in 2019. He is currently Consultant Physician and Endocrinologist with practice in Subang Jaya Medical Centre and Park City Medical Centre and Hospital Sultan Haji Ahmad Shah, Temerloh. He is currently the Honorary Treasurer of Malaysian Endocrine and Metabolic Society (2024-2026). He is an active peer reviewer with the Journal of ASEAN Federation of Endocrine Society (JAFES) and steering committee member of the Changing Diabetes in Children program. He has avid interest in conducting clinical audits and research and participates actively educational programmes nationally and regionally. He has special interest in Men’s Health Issues, Young Diabetes, Diabetes Technology, Thyroid disorders and Acromegaly.

21 MARCH

Time	Session

10:20 11:10	Oral Presentation 4: Metabolic Synergy: Diabetes & Obesity Management Chee Keong SeeMalaysia Moderator AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia Dicky L. TahaparyIndonesia Moderator Precision Diabetes Clustering for Young-Onset Diabetes (in Indonesia Populations) 201BC

22 MARCH

Time	Session

14:00 15:30	ESROC–MEMS Joint Symposium Digital Endocrinology, Wearables, and Future Therapeutics in Asia Waye Hann KangMalaysia Moderator Yi-Sun YangTaiwan Moderator Impaired Fasting Glucose and Musculoskeletal DisordersThe Continuum of Glycemic Dysregulation and Musculoskeletal Health: From Impaired Fasting Glucose to Established Diabetes. As the global medical community transitions into the "Next ERA" of endocrinology, there is an urgent need to broaden our focus beyond traditional microvascular and macrovascular complications toward the pervasive, yet often neglected, musculoskeletal (MS) burden associated with dysglycemia. While the debilitating effects of established Type 2 Diabetes Mellitus (T2DM) on physical function are well-documented, emerging clinical evidence suggests that the musculoskeletal system is an early "silent" target of metabolic injury, with pathological changes manifesting as early as the Impaired Fasting Glucose (IFG) stage. This presentation explores the MS burden across the full glycemic spectrum, highlighting how the transition from normoglycemia to IFG, and ultimately to T2DM, correlates with a progressive increase in chronic pain, structural tissue damage, and functional disability. Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models Jun-Sing WangTaiwan Speaker Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia Chee Keong SeeMalaysia Speaker AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors Yen Bo LinTaiwan Speaker Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and Beyond Siew Hui FooMalaysia Speaker Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and BeyondThe role of incretin-based therapy is taking the front seat globally due to the high prevalence of obesity, diabetes and related complications worldwide. Similar scene is expected to take place in South East Asia that is facing the escalating burden of obesity driving up the already high burden of type 2 diabetes especially in the younger population despite consisting of relatively small countries in areas and population. This poses adverse socio-economic impact to the region due to increased risk of premature complications and death among the young in a region that is largely still developing. The arrival of incretin-based therapy into South East Asia since the first daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection in 2010 has picked up its pace in the last 5 years with the entry of weekly GLP-1 RA injection, oral GLP-1 RA and GLP-1 RA / GIP (glucose-dependent insulinotropic polypeptide) injection. This lecture will address the evidence behind its efficacy, tolerability as well as cardiovascular effects of these agents in the Asian populations. The future shift to the more potent high-dose GLP-1 receptor mono-agonist, dual, triple incretin receptor multi-agonist and beyond as these agents are approved for treatment for the twin epidemics of type 2 diabetes, obesity and related complications will be discussed along with the challenges especially on unequitable access, healthcare disparities, unregulated dispensing and the importance of a strengthened health system with multi-sectoral cooperation at the regional level to mitigate these issues. Discussion 103

Time

Session

14:00

15:30

ESROC–MEMS Joint Symposium

Digital Endocrinology, Wearables, and Future Therapeutics in Asia

Waye Hann KangMalaysia Moderator

Yi-Sun YangTaiwan Moderator Impaired Fasting Glucose and Musculoskeletal DisordersThe Continuum of Glycemic Dysregulation and Musculoskeletal Health: From Impaired Fasting Glucose to Established Diabetes. As the global medical community transitions into the "Next ERA" of endocrinology, there is an urgent need to broaden our focus beyond traditional microvascular and macrovascular complications toward the pervasive, yet often neglected, musculoskeletal (MS) burden associated with dysglycemia. While the debilitating effects of established Type 2 Diabetes Mellitus (T2DM) on physical function are well-documented, emerging clinical evidence suggests that the musculoskeletal system is an early "silent" target of metabolic injury, with pathological changes manifesting as early as the Impaired Fasting Glucose (IFG) stage. This presentation explores the MS burden across the full glycemic spectrum, highlighting how the transition from normoglycemia to IFG, and ultimately to T2DM, correlates with a progressive increase in chronic pain, structural tissue damage, and functional disability.

Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models

Jun-Sing WangTaiwan Speaker Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models
AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia

Chee Keong SeeMalaysia Speaker AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia
Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors

Yen Bo LinTaiwan Speaker Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors
Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and Beyond

Siew Hui FooMalaysia Speaker Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and BeyondThe role of incretin-based therapy is taking the front seat globally due to the high prevalence of obesity, diabetes and related complications worldwide. Similar scene is expected to take place in South East Asia that is facing the escalating burden of obesity driving up the already high burden of type 2 diabetes especially in the younger population despite consisting of relatively small countries in areas and population. This poses adverse socio-economic impact to the region due to increased risk of premature complications and death among the young in a region that is largely still developing. The arrival of incretin-based therapy into South East Asia since the first daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection in 2010 has picked up its pace in the last 5 years with the entry of weekly GLP-1 RA injection, oral GLP-1 RA and GLP-1 RA / GIP (glucose-dependent insulinotropic polypeptide) injection. This lecture will address the evidence behind its efficacy, tolerability as well as cardiovascular effects of these agents in the Asian populations. The future shift to the more potent high-dose GLP-1 receptor mono-agonist, dual, triple incretin receptor multi-agonist and beyond as these agents are approved for treatment for the twin epidemics of type 2 diabetes, obesity and related complications will be discussed along with the challenges especially on unequitable access, healthcare disparities, unregulated dispensing and the importance of a strengthened health system with multi-sectoral cooperation at the regional level to mitigate these issues.
Discussion

103